A spliceosome is a large molecular machine inside your cells that edits genetic messages before they can be used to build proteins. It works by cutting out non-coding segments from raw RNA copies of your genes and stitching the remaining useful segments together. This editing step is essential: without it, your cells couldn’t produce functional proteins from the vast majority of human genes.
The spliceosome is one of the largest and most complex structures in the cell, weighing in at roughly 3 million daltons (for comparison, a single protein molecule is typically 10,000 to 100,000 daltons). It’s built from five small RNA molecules and over 70 proteins in simpler organisms, with even more components in human cells. Understanding what it does, how it works, and what happens when it breaks down helps explain everything from how 20,000 genes can produce hundreds of thousands of different proteins to why certain genetic diseases affect only specific tissues in the body.
Why Your Cells Need a Spliceosome
When a gene is first copied into RNA, the resulting message contains both coding segments (called exons) and non-coding segments (called introns). The introns need to be precisely removed before the RNA can serve as instructions for building a protein. This editing process is called pre-mRNA splicing, and the spliceosome is the machinery that carries it out.
The process also explains a puzzle about the human genome. Humans have only about 20,000 genes, yet our bodies produce a far larger and more complex set of proteins. The spliceosome makes this possible through alternative splicing, where exons from the same gene are joined in different combinations to produce different, but related, RNA messages. A gene with seven exons can potentially generate hundreds of distinct protein variants. This is a core reason human biology can be so complex while relying on a relatively modest number of genes.
What the Spliceosome Is Made Of
The spliceosome is assembled from five major building blocks, each one a small nuclear ribonucleoprotein particle (snRNP, pronounced “snurp”). These are named U1, U2, U4, U5, and U6. Each snRNP contains a small RNA molecule wrapped in a set of proteins. They don’t form a permanent structure sitting idle in the cell. Instead, they assemble fresh on each RNA message that needs editing, carry out their work, then disassemble.
Inside the nucleus, these components are scattered in a patchy pattern throughout the space where chromosomes live, avoiding the dense region called the nucleolus. U1 tends to spread more widely than the others, likely because it has a role in the earliest recognition step when a new RNA message appears. Additional non-snRNP proteins also participate, acting as helper factors that guide the machinery to the right cutting points and ensure accuracy.
How the Spliceosome Removes Introns
Splicing happens in two main chemical steps, both involving a reaction where one part of the RNA swaps a chemical bond with another. In chemistry terms, these are called transesterification reactions.
In the first step (called branching), the spliceosome positions a specific nucleotide within the intron so that it attacks the junction between the first exon and the start of the intron. This cuts the RNA at that point and creates an unusual loop-shaped structure called a lariat, where the intron curls back on itself. At this stage, the first exon is free-floating while the lariat remains attached to the second exon.
In the second step (called exon ligation), the free end of the first exon attacks the junction between the intron lariat and the second exon. This simultaneously joins the two exons together and releases the intron lariat as waste. The result is a clean, continuous RNA message ready to be translated into protein.
What makes this remarkable is the precision involved. During the first step, segments of the spliceosome’s own RNA and the intron physically move 50 to 100 angstroms (billionths of a centimeter) to bring the reacting parts close enough to interact. Dedicated helper proteins stabilize the machinery at each stage, then swap out for a different set of helpers before the second step can proceed. The entire cycle is tightly choreographed to prevent errors that could scramble the protein’s instructions.
The Minor Spliceosome
Most introns in human genes are removed by the major spliceosome described above, sometimes called the U2-dependent spliceosome. But a second, rarer version exists: the minor spliceosome, also called the U12-dependent spliceosome. It handles a small class of introns that make up less than 1% of all introns in mammals.
The minor spliceosome uses four unique RNA components, named U11, U12, U4atac, and U6atac, which mirror the roles of U1, U2, U4, and U6 in the major spliceosome. It shares U5 and most of its proteins with the major spliceosome, but has seven proteins found only in its own machinery. Despite processing so few introns, the minor spliceosome is essential. The genes that contain these rare introns are often involved in critical cellular functions, so disrupting the minor spliceosome can have serious consequences.
What Happens When Splicing Goes Wrong
Mutations in the genes encoding spliceosome components cause a group of diseases collectively called spliceosomopathies. One of the puzzling features of these diseases is their tissue specificity: even though the spliceosome operates in every cell type, a given mutation tends to affect only certain tissues.
Retinitis pigmentosa, a genetic disorder that causes gradual deterioration of light-sensing cells in the retina and can lead to blindness, is one example. More than 50 genes have been linked to this condition, and several of them encode splicing factors. The mutations responsible are almost exclusively found in components associated with the U4/U6 complex, one specific part of the spliceosome’s assembly.
Spinal muscular atrophy (SMA) offers another well-studied example. SMA is characterized by progressive loss of motor neurons in the spinal cord and is linked to mutations in a gene called SMN1, which produces a protein needed to assemble snRNPs in the first place. Without enough functional snRNP assembly, splicing throughout the cell is compromised, but motor neurons are disproportionately affected.
Myelodysplastic syndromes, a group of blood cancers, and mandibulofacial dysostosis, which affects craniofacial bone development, round out the major categories of spliceosomopathies. In each case, the same universal machinery malfunctions, but only specific tissues show symptoms.
Medicines That Target Splicing
The deepening understanding of splicing has already led to approved therapies. The most prominent is nusinersen (sold as Spinraza), the first drug approved for spinal muscular atrophy. Rather than replacing the broken SMN1 gene, nusinersen works on a backup gene called SMN2. Under normal conditions, SMN2 skips a critical segment during splicing, producing a protein that doesn’t work well. Nusinersen is a short synthetic strand of modified genetic material that binds to a specific silencing sequence in the SMN2 RNA, blocking it. This causes massive structural rearrangements in the RNA that allow the spliceosome’s U1 component to engage properly, restoring inclusion of the skipped segment. The result is a functional protein, even though the original SMN1 gene remains broken. The drug is effective at concentrations as low as 5 nanomolar in cell studies.
How Scientists Mapped the Spliceosome
For decades, the spliceosome’s size, flexibility, and habit of constantly reshuffling its components made it nearly impossible to study in detail. That changed with advances in cryo-electron microscopy (cryo-EM), a technique that flash-freezes molecules and images them with an electron beam. This approach triggered what researchers call a “resolution revolution,” allowing scientists to capture near-atomic snapshots of the spliceosome at multiple stages of its cycle.
These frozen snapshots have revealed how the spliceosome activates, how it positions the RNA precisely for each chemical step, and how energy-burning enzymes drive rearrangements between stages. In human cells, cryo-EM structures also showed that the spliceosome deposits a molecular tag on the finished RNA about 20 to 25 nucleotides before the point where two exons were joined. This tag, later read by the ribosome during protein production, plays a role in quality control, helping the cell verify that the splicing was done correctly.